The increasing prevalence of bacteremia caused by gram-positive bacteria in granulocytopenic acute leukemia patients prompted us to evaluate, in a prospective randomized trial, the role of teicoplanin, a new glycopeptide antibiotic, when it was added to amikacin plus ceftazidime, as an empiric therapy of fever in these patients. Of 47 evaluable episodes, 22 were treated with the teicoplanin regimen and 25 were treated with the combination of amikacin and ceftazidime. The overall response to therapy of patients treated with teicoplanin was slightly better (82% improvement) than that obtained with amikacin plus ceftazidime (52%). The response rate of patients with gram-positive bacteremias was 80% (4 of 5) to the regimen that included teicoplanin; 25% (1 of 4) of the patients treated with amikacin plus ceftazidime responded to treatment; and for patients with gram-negative bacteremias, the response rates were, respectively, 100% (4 of 4) and 70% (7 of 10). The better results obtained with amikacin-ceftazidime-teicoplanin treatment were most evident in patients with profound (<100/mm3) and persistent neutropenia (83 versus 30% improvement). Furthermore, a good response rate of patients with gram-positive bacteremias (seven of eight; 87% improvement) was achieved in a small group of bone marrow transplant patients who were all treated with amikacin-ceftazidime-teicoplanin. No severe side effects were documented in any patient. Teicoplanin, as a drug administered as a single daily dose, seems to be a safe and useful anti-gram-positive agent when used in combination with amikacin-ceftazidime as an empiric therapy of febrile episodes in granulocytopenic acute leukemia patients.
Changes in the relative prevalence of bacterial pathogens among granulocytopenic cancer patients have been observed in many centers and in numerous large clinical trials. Not only has the frequency of gram-positive bacteremias increased in recent years, but the clinical and microbiological picture of gram-positive infections has changed as well (6, 8, 10, 12) . The rmortality rate for these infections has increased (6) , and many staphylococcal strains have become resistant to beta-lactam antibiotics and the aminoglycosides. Therefore, the antimicrobial regimens designed for empiric therapy in granulocytopenic patients, such as the combination of a beta-lactam and an aminoglycoside (2), do not satisfactorily cover the spectrum of gram-positive infections, especially those caused by methicillin-resistant strains of staphylococci or enterococci.
A rational choice would be the addition of vancomycin or a similar drug to these regimens. Teicoplanin is a new glycopeptide antibiotic, chemically related to vancomycin (9) . It is active against aerobic and anaerobic gram-positive bacteria only, including methicillin-resistant staphylococci, group D streptococci, Clostridium difficile, and group JK corynebacteria. Teicoplanin, therefore, has the same antibacterial spectrum that vancomycin has, with the added advantage of a long half-life, allowing once-a-day administration (1, 4; S. Pauluzzi, A. Del Favero, F. Menichetti, E. Baratta, M. V. Moretti, P. Di Filippo, M. B. Pasticci, R. Guerciolini, R. F. Frongillo, and L. Patoia, J. Antimicrob. Chemother., in press).
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The aim of this study was to evaluate the comparative efficacy and safety of a standard empiric antibiotic treatment (amikacin plus ceftazidime) with or without teicoplanin in granulocytopenic, febrile acute leukemia patients.
MATERIALS AND METHODS
Consecutive patients with acute leukemia admitted to the First Internal Medicine Institute of Perugia General Hospital were eligible for this study if they had an absolute granulocyte count below 1,000/mm3 and an axillary temperature of 38°C or more in the absence of obvious noninfective causes of fever. Patients who had a history of an allergy to any of the three classes of antibiotics used or who in the previous 5 days had received systemic antibiotics were excluded from the study prior to randomization. Also excluded were patients having a creatinine level in serum above 2 mg/100 ml.
Random grouping of patients was achieved by using consecutive sealed envelopes assigning patients to regimens of either amikacin plus ceftazidime or these two drugs plus teicoplanin as determined by random permuted blocks. Amikacin was given at the dosage of 15 mg/kg per day divided in three equal doses (maximum daily dose, 1 g), which were subsequently adjusted to maintain optimal peak (15 to 25 mg/liter) and trough (<5 mg/liter) levels in serum (Abbott-TDX). Ceftazidime was given at the dosage of 90 mg/kg per day divided in three equal doses (maximum daily dose, 6 g). Each antibiotic was dissolved in 100 ml of 0.9% saline and administered intravenously over 15 to 30 min. Teicoplanin was given at the dosage of 5 mg/kg per day in a single daily dose (maximum daily dose, 400 mg) dissolved in Blood cell counts and differential leukocyte counts, determinations of electrolytes and creatinine in serum, blood cultures, and culture specimens from infection sites were obtained every 3 days during the study and within 72 h after discontinuation of the drugs studied.
Febrile episodes were classified according to the definitions of the European Organization for Research on Treatment of Cancer (3). Response to therapy was evaluated 72 to 96 h after the beginning of empiric treatment, when the antimicrobial susceptibility data were generally available, and was classified as previously indicated (11) . One or more of the investigators examined all protocol patients daily. Patients who responded to therapy remained on the study drugs -for at least 5 days after all signs of infection had disappeared; a change in therapy was taken into consideration 72 to 96 h after randomization in patients evaluated as nonresponsive to the treatment. Teicoplanin was stopped in patients with documented bacteremia caused by gramnegative bacilli.
Antibiotic-related nephrotoxicity was defined as an increase in the creatinine level in serum of more than 0.4 mg/100 ml from normal base line when other causes of nephrotoxicity (hypotension or another nephrotoxic drug) were excluded. Besides clinical evaluation, no audiometric studies were performed for ototoxicity evaluation.
The Yates corrected chi-square test was used for comparing significant differences in proportion.
RESULTS
Over a 14-month period, 66 febrile episodes (54 patients) were randomly assigned to regimens as follows: 33 to the amikacin-ceftazidime-teicoplanin regimen and 33 to the amikacin-ceftazidime regimen. Patient characteristics are illustrated in Table 1 and are equally distributed in both groups.
Of all febrile episodes, 71% (47 of 66) were considered evaluable for analysis. Reasons for exclusion from analysis were as follows (amikacin-ceftazidime-teicoplanin/amikacinceftazidime groups): doubtful infections (7/7), nonbacterial infections (2/0), protocol violation (1/1), and length of therapy <24 h (1/0).
The results of treatment are shown in Table 2 . The overall response achieved with the regimen that included teicoplanin was good (82%; 18 of 22 showed improvement) and better than that found with the amikacin-ceftazidime regimen (56%; 14 of 25 showed improvement), although this difference is not statistically significant (P = 0.1). The improvement rates in microbiologically documented infection were 92% (11 of 12) in patients treated with the regimen that included teicoplanin and 60% (9 of 15) in patients treated with amikacin-ceftazidime. The types and sensitivities of isolated pathogens were similar in the two groups. The response rate of patients with gram-positive bacteremias was higher to the teicoplanin regimen (4 of 5 versus 1 of 4), but equal benefit for gram-negative bacteremias was found (4 of 4 versus 7 of 10) ( Table 3 ). The observed better response in patients treated with teicoplanin was most evident in those with profound (<100/mm3) and persistent neutropenia (83 versus 30%) ( required CVC removal. The only treatment failure was represented by a patient with a bacteremia caused by enterococci. In this patient, the bacteremia was cleared, but owing to the persistence of fever, antibiotic therapy was changed.
Side effects were minor and did not require the intetruption of treatment in any patient. In patients treated with three drugs versus those treated with two drugs, hypokalemia (six versus three) and drug fever (zero versus one) were the only side effects obsetved. In particular, no "red man" syndrome and no clinical evidence of ototoxicity or nephrotoxicity were documented, and no differences in evolution of neutropenia were fouhd between, the two groups. Severe hypocalcemnia was observed in one patient treated for 2 weeks concomitantly with teicoplaninamikacin-ceftazidime and amphotericin B.
DISCUSSION
Ouir study shows that the empiric treatment of febrile episodes in granulocytopenic acute leukemia patients by a three-drug combination that included the new glycopeptide antibiotic teicoplanin is characterized by a very high success rate (82% overall improvement). These results tend to be better than those obtained with the standard two-drug combin'ation (56% overall improvement), although this difference is not statistically significant owing to the small number of patients enrolled in the study.
The higher response rate of the regimen that included teicoplanin was most evident in the treatment of infections caused by gram-positive organisms. The cure rates of grampositive bacteremias were in fact 80% (four of five) in teicoplaniri-treated patients bui only 25% (one of four) in patients treated with amikacin-ceftazidime. On the other hand, the response rate of patients with bacteremias caused by gram-negative bacilli was as good with the three-drug treatment (4 of 4) as it was with the two-drug treatment (7 of 10). This slightly greater response rate, even for patients with gram-negative bacteremias, achieved by the regimen that included teicoplanin cannot be owing to the direct effect of teicoplanin on gram-negative bacilli but is probably casual, owing to the smaller number of patients with gramnegative bacteremias included in the teicoplanin-treated group (4 versus 10).
The good results obtained in the three-drug treatment of gram-positive bacteremias in the acute leukemia patients are confirmed by our experience in bone marrow transplant patients: seven of eight gram-positive, CVC-related bacteremias were cleared and only one required catheter removal.
It is also noteworthy that the patients showing the greatest advantage from the regimen that included teicoplanin were those with profound (<100/mm3) and persistent neutropenia (83%o improvement versus 30% for the patients treated witli only two drugs).
Tolerance of the teicoplanin regimen was also very good.
Side effects of the three-drug regimen were minor and comparable to those foutd with the two drugs. It should be noted, however, that no formal evaluation of ototoxicity was carried out. No difference in evolution of neutropenia between the two groups was found, and this is important in view of those rare cases of reversible leucopenia probably related to teicoplanin that have been reported (G. Buniva, data on file at LepetitMerrel Dow, Milan, Italy). Recent data (5, 7) suggest the advantage of using a triple-drug combination including an antistaphylococcal drug in the treatment of gram-positive bacteremias in acute leukemia patients. Our results show that teicoplanin can be successfully used in combination with amikacin and ceftazidime in these patients.
